Articles
Effect of FenuLife® on blood glucose in type-II diabetes
By Dr. Hiroyuki Abe, Associate Professor of Kyourin University, Japan
FenuLife® EXTRA contains a minimum of 85% of galactomannans, which are indicated to balance sugar absorption in the small intestine, thereby decreasing spikes in blood sugar following a meal. A study was designed to investigate if FenuLife® EXTRA influences serum glucose in type-II diabetic patients.
Study design
17 Japanese type-II diabetic patients (16 male & 1 female) were divided into 2 groups according to their blood sugar levels. Group A (n=12) had fasting serum glucose levels of 120-200 mg/dl; group B (n=5) was characterized by blood sugar levels > 200 mg/dl. Group A was additionally randomly subdivided into 2 groups of 6 persons (A1 and A2) to receive a different treatment. During the test period of 8 weeks and 2 weeks before, group A could not take diabetic drugs, but group B could. FenuLife® EXTRA and placebo (lactose) were provided in hard-gelatin capsules, which were taken 30 minutes before each meal with 200 ml water.
| Treatment per group | First 4 weeks | Sec. 4 weeks |
|---|---|---|
| A1 Light / moderate diabetes | 4 gr placebo / day | 4 gr FenuLife® / day |
| A2 Light / moderate diabetes | 4 gr FenuLife® / day | 4 gr FenuLife® / day |
| B Moderate / severe diabetes | 2 gr FenuLife® / day | 2 gr FenuLife® / day |
Conclusion
Fasting blood sugar levels were measured at starting point, and at 4 and 8 weeks (see graphs). In all groups FenuLife® reduced serum glucose levels. Upon reaching a desired blood sugar level, a reduced intake of FenuLife® showed to maintain the serum glucose level. Additionally, FenuLife® created a complementary effect on reduction of blood sugar levels along with use of conventional diabetic drugs.
